$INO 50% upside potentialNASDAQ:INO had a streak of green weeks recently and currently is trading above a significant resistance at $11.96
- MACD weekly just turned positive
- Vortex index is positive
−6.11USD
−135.12 MUSD
832.01 KUSD
22.99 M
About Inovio Pharmaceuticals, Inc.
Sector
CEO
Jacqueline E. Shea
Headquarters
Plymouth Meeting
Website
Employees (FY)
122
Founded
1983
ISIN
US45773H4092
FIGI
BBG000BK6YX5
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
INO 1D 2 Month Larger TF shows continuation. Time/Space corrective until wave (B). Breakout of falling wedge finished. Retracement and continuation.
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases a
INO Bullish Deep CrabINO has completed a bottom formation IMO. I believe the bottom has come in a harmonic deep crab formation. I've highlighted the accumulation zone. This is high risk but also has the potential of being a 5 to 100x bagger. Good Luck!
💊 INO SELL THE BREAK 📉INO has broken out of a larger degree correction and continues to make smaller degree flags in the bearish direction.
Stick to your trading rules!
Inovio timeCovid is here to stay!
Data from the WHO will be good. Time to buy and hold. Let the shorts
INO 1W 168% from $1.92Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was found
inovio will hit rock bottom and will make you rich, unless, Unless the company ends bad . .
i wouldnt know as i only read charts and follow trend .
i say that ino will hit the 47-50c mark , but hey , take a look at its highest high : $180
ok im not that positive or healthy to live another 30 years or so ,... but it might be a stock worth following .
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of INO is 9.76 USD — it has decreased by 4.31% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inovio Pharmaceuticals, Inc. stocks are traded under the ticker INO.
Inovio Pharmaceuticals, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
INO stock is 6.14% volatile and has beta coefficient of 1.31. Check out the list of the most volatile stocks — is Inovio Pharmaceuticals, Inc. there?
One year price forecast for Inovio Pharmaceuticals, Inc. has a max estimate of 40.00 USD and a min estimate of 8.00 USD.
INO earnings for the last quarter are −1.56 USD per share, whereas the estimation was −1.52 USD resulting in a −2.63% surprise. The estimated earnings for the next quarter are −1.19 USD per share. See more details about Inovio Pharmaceuticals, Inc. earnings.
Inovio Pharmaceuticals, Inc. revenue for the last quarter amounts to 388.45 K USD despite the estimated figure of 116.67 K USD. In the next quarter revenue is expected to reach 360.00 K USD.
Yes, you can track Inovio Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
INO stock has fallen by 16.37% compared to the previous week, the month change is a 8.27% fall, over the last year Inovio Pharmaceuticals, Inc. has showed a 6.29% decrease.
INO net income for the last quarter is −25.00 M USD, while the quarter before that showed −33.93 M USD of net income which accounts for 26.31% change. Track more Inovio Pharmaceuticals, Inc. financial stats to get the full picture.
Today Inovio Pharmaceuticals, Inc. has the market capitalization of 238.38 M, it has decreased by 8.62% over the last week.
No, INO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, INO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inovio Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 122.00 employees. See our rating of the largest employees — is Inovio Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Inovio Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Inovio Pharmaceuticals, Inc. stock shows the sell signal. See more of Inovio Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Inovio Pharmaceuticals, Inc. future price: according to them, INO price has a max estimate of 40.00 USD and a min estimate of 8.00 USD. Read a more detailed Inovio Pharmaceuticals, Inc. forecast: see what analysts think of Inovio Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Inovio Pharmaceuticals, Inc. EBITDA is −129.92 M USD, and current EBITDA margin is −15.83 K%. See more stats in Inovio Pharmaceuticals, Inc. financial statements.